Financial Data and Key Metrics Changes - Total revenue grew 49% year over year to a record of almost $72 million in Q2 2025, driven by strong demand across the product portfolio [5][14] - Net product revenue increased 46% to approximately $67.7 million, with RECORLEV leading the growth [14][15] - Adjusted EBITDA was positive at $12.5 million, reflecting an improvement of nearly $13 million year over year [19] Performance by Product Line - RECORLEV revenue reached over $31 million, a 136% increase year over year, with a 122% increase in the average number of patients on therapy [7][14] - Gvoke generated $23.5 million in revenue, a 17% increase compared to the previous year, supported by a 5% growth in total prescriptions [15][10] - KEVEYIS revenue was over $11.5 million, showing a modest increase in the average number of patients on therapy [10][15] Market Data and Key Metrics Changes - The company anticipates total revenue for 2025 to be in the range of $280 million to $290 million, representing a year-over-year growth of 40% at the midpoint [6][20] - The hypercortisolism market is expanding, with increased attention on cortisol testing, which is expected to benefit all players in the market [29] Company Strategy and Development Direction - The company is focused on strategic investments to drive sustained growth, particularly in RECORLEV and the pipeline asset XP-8121 [12][21] - The company plans to expand its commercial footprint and increase investments to support the dynamic growth in the hypercortisolism market [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong performance and growth opportunities ahead, citing the positive trajectory of commercial products [6][13] - The company remains committed to delivering continued positive adjusted EBITDA while making deliberate value-driven investments [22] Other Important Information - The company celebrated the ten-year anniversary of KEVEYIS' FDA approval, highlighting its importance in treating patients with primary periodic paralysis [10] - The company is leveraging proprietary technology to develop a novel formulation for XP-8121, targeting a significant unmet medical need in hypothyroidism [12] Q&A Session Summary Question: Can you talk about the gross to net benefit for Gvoke? - Management anticipates that the favorability will continue for the balance of the year [23] Question: How do you see the script growth for Gvoke in the back half of the year? - Management expects an increase in script growth in Q3, typically a stronger quarter due to back-to-school movements [26] Question: Where are RECORLEV prescriptions coming from? - The majority of prescriptions are from endocrinologists, with over half of patients being new to therapy [27] Question: How will the competitive environment change with a new drug launch? - Management believes that more players in the market will generate more awareness and growth opportunities for all [29] Question: What are the plans for long-term spending to support RECORLEV? - The company plans to increase its commercial footprint and make significant investments in the RECORLEV brand [34] Question: Will there be further clinical data generated for RECORLEV? - Management confirmed plans to generate more data to solidify RECORLEV's value proposition [37] Question: How do you see the treatment landscape for Gvoke evolving? - There is significant opportunity to reach patients who currently do not have access to rescue glucagon, with a large number of patients still unprotected [41]

Xeris Biopharma Holdings (XERS) 2025 Conference June 04, 2025 01:25 PM ET Speaker0 Health care conference day one. My name is Dennis Ding. I'm the biotech analyst here at Jefferies. I have the pleasure of having Xeris Biopharma here. We have CEO John Shannon as well as CFO Steve Piper here. Welcome. Speaker1 Thank you. Welcome. Speaker2 Yes, thanks for having us. Speaker0 So maybe to kick things off, just level set us in terms of where you are as a company and maybe talk also about the progress you have mad ...

Xeris Biopharma Holdings (XERS) 2025 Investor Day June 03, 2025 10:00 AM ET Speaker0 Could everyone woah. Take their seats, please. Because we do have people on a live webcast so we want to start on time for them. Okay, two minutes. So everyone, this is your chance to turn your phones off for the ringers. Thank you. I can do it with a whistle, but that's really loud with a mic. Thank you everybody for coming to our very first Analyst and Investor Day. I appreciate you taking the time out of your day and the ...

Xeris Biopharma Holdings (XERS) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate CommunicationsJohn Shannon - CEOSteve Pieper - Chief Financial OfficerMazahir Alimohamed - Biotech Equity Research AssociateJason Dorr - Associate Director Conference Call Participants David Amsellem - Sr. Research AnalystChase Knickerbocker - Senior Equity Research Analyst - Healthcare Operator Good morning. Thank you for attending today's ...

Xeris Biopharma Holdings (XERS) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning. Thank you for attending today's Verisk Biopharma First Quarter twenty twenty five Results Conference Call. My name is Makayah, and I'll be the moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for your questions and answers at the end. At this time, I would like to pass the call over to our Senior Vice President of Investor Relations and Corp ...